Skip to main content
Premium Trial:

Request an Annual Quote

Servier Licenses Cellectis Cell Lines

NEW YORK (GenomeWeb News) – French drug firm Servier has licensed non-exclusive rights to use Cellectis' π10 modified cell lines for high-throughput screening efforts.

The new agreement follows a recently concluded research pact between the firms that began in 2007.

"The cells, gene insertion templates and meganuclease used by Servier are now available as a commercial kit, which provides a reliable, easy-to-use method of creating cell lines specific to drug targets of interest," said Marc Le Bozec, CEO and CFO of Cellectis BioResearch, the subsidiary of Cellectis that markets the kits.

Financial and other terms were not disclosed.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.